Genenta Science S.p.A. is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™.

SCENARIO

– Genenta was seeking new capital to advance clinical trials in order to:

– carry out phase 2 clinical trials of the Temferon product in Italy

– fund Temferon manufacturing activities for the phase 2 study

– finanziare le attività di produzione di Temferon per lo studio della fase 2

THE ADVISOR’S SUPPORT

Growth Capital has advised Genenta’s management team.